Biopharma · FDA Approvals · Stock

CALC CalciMedica

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of…

Assets on file: Auxora

Start live analysis of CALC Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for CALC, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for CALC, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Jun 24, 2026

09:02 PM

CALCCalciMedica, Inc.

CalciMedica: FDA clears KOURAGE trial to resume after safety review

FDA completed its review of the KOURAGE protocol amendment and interim safety data with no comments or questions, confirming the trial may resume dosing. The review was not a formal clinical-hold response but validates the revised design and safety package. CalciMedica separately expects FDA feedback on a potential pivotal program in acute pancreatitis in Q3 2026.

Manufacturing inspectionSEC 8-K Open record